Skip to main content

Table 1 Study participants categories in Indonesia, Kyrgyzstan, Nigeria and all countries combined

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

 

Qualitative part

Quantitative part

Total

Indonesiaa

Kyrgyzstan

Nigeria

Total

Indonesiaa

Kyrgyzstan

Nigeria

Total

188

51

63

74

182

48

63

71

Health care workers

110

28

44

38

110

28

44

38

Laboratory stakeholders

78

23

12

9

72

20

12

9

Programmatic Stakeholders

7

27

7

24

  1. aThe categories laboratory and programmatic stakeholders were merged to ensure anonymity